Celldex Therapeutics | CLDX - Betriebsaufwand





Betriebsaufwand Veränderung Datum
AbbVie USD 10.27B 538M 2026-03
Agenus USD 19.81M 293.94M 2025-12
Amgen USD 4.78B 1.12B 2026-03
Bristol-Myers Squibb USD 20.07B 11.77B 2026-03
Celldex Therapeutics USD 87.27M 511.09M 2025-12
Glaxosmithkline GBP 9.17B 1.4B 2025-12
Nektar Therapeutics USD 40.9M 44.19M 2025-12
Northwest Biotherapeutics USD -108.65M 8.26M 2025-09
Pfizer USD 90.1B 77.19B 2026-03
Rigel Pharmaceuticals USD 117.61M 35.67M 2025-09
Roche Holding CHF 21.01B 10.84B 2025-12